{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?page=15&sponsor=Genentech%2C+Inc.", "query": { "sponsor": "Genentech, Inc.", "page": 15 }, "page_size": 10 }, "pagination": { "page": 15, "page_size": 10, "total_count": 1396, "total_pages": 140, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?page=16&sponsor=Genentech%2C+Inc.&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?page=14&sponsor=Genentech%2C+Inc.&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-23T12:35:30.170Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT01296555", "title": "A Dose Escalation Study Evaluating the Safety and Tolerability of GDC-0032 in Participants With Locally Advanced or Metastatic Solid Tumors or Non-Hodgkin's Lymphoma (NHL) and in Combination With Endocrine Therapy in Locally Advanced or Metastatic Hormone Receptor-Positive Breast Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Solid Cancers", "Non-Hodgkin's Lymphoma" ], "interventions": [ { "name": "Fulvestrant", "type": "DRUG" }, { "name": "GDC-0032", "type": "DRUG" }, { "name": "Letrozole", "type": "DRUG" }, { "name": "Midazolam", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Genentech, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 674, "start_date": "2011-03-16", "completion_date": "2021-06-25", "has_results": true, "last_update_posted_date": "2024-07-31", "last_synced_at": "2026-10-23T12:35:30.170Z", "location_count": 27, "location_summary": "Scottsdale, Arizona • Tucson, Arizona • Orange, California + 20 more", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Orange", "state": "California" }, { "city": "Sacramento", "state": "California" }, { "city": "San Francisco", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01296555" }, { "nct_id": "NCT05859217", "title": "A Study of Combining Cabozantinib and Atezolizumab for Advanced/Metastatic NSCLC (Cabatezo-1)", "overall_status": "NOT_YET_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Lung Cancer", "NSCLC Stage IV", "Metastatic NSCLC - Non-Small Cell Lung Cancer", "Advanced NSCLC" ], "interventions": [ { "name": "Cabozantinib", "type": "DRUG" }, { "name": "Atezolizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Jun Zhang, MD, PhD", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 40, "start_date": "2024-12", "completion_date": "2028-06", "has_results": false, "last_update_posted_date": "2024-05-08", "last_synced_at": "2026-10-23T12:35:30.170Z", "location_count": 4, "location_summary": "Kansas City, Kansas • Overland Park, Kansas • Kansas City, Missouri + 1 more", "locations": [ { "city": "Kansas City", "state": "Kansas" }, { "city": "Overland Park", "state": "Kansas" }, { "city": "Kansas City", "state": "Missouri" }, { "city": "Lee's Summit", "state": "Missouri" } ], "official_url": "https://clinicaltrials.gov/study/NCT05859217" }, { "nct_id": "NCT00140413", "title": "Endocrine Dysfunction and Growth Hormone Deficiency in Children With Optic Nerve Hypoplasia", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Growth Hormone Deficiency", "Septo-Optic Dysplasia", "Hypopituitarism" ], "interventions": [ { "name": "Nutropin AQ", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Children's Hospital Los Angeles", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": "5 Years", "sex": "ALL", "summary": "Up to 5 Years" }, "enrollment_count": 20, "start_date": "2004-12", "completion_date": "2014-02", "has_results": true, "last_update_posted_date": "2015-04-01", "last_synced_at": "2026-10-23T12:35:30.170Z", "location_count": 1, "location_summary": "Los Angeles, California", "locations": [ { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00140413" }, { "nct_id": "NCT00586508", "title": "Trial of Enzastaurin and Bevacizumab in Participants With Recurrent Malignant Gliomas", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Recurrent Glioblastoma" ], "interventions": [ { "name": "enzastaurin", "type": "DRUG" }, { "name": "bevacizumab", "type": "DRUG" }, { "name": "Enzyme-inducing antiepileptic drugs (EIAED)", "type": "DRUG" }, { "name": "Non-enzyme inducing antiepileptic drugs (NEIAED)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Eli Lilly and Company", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 81, "start_date": "2007-11", "completion_date": "2013-10", "has_results": true, "last_update_posted_date": "2020-09-24", "last_synced_at": "2026-10-23T12:35:30.170Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT00586508" }, { "nct_id": "NCT00095225", "title": "A Study to Evaluate Bevacizumab and Chemotherapy or Tarceva in Treating Recurrent or Refractory NSCLC (Non-Small Cell Lung Cancer)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Non-Small-Cell Lung Carcinoma", "Neoplasm Recurrence, Local" ], "interventions": [ { "name": "Avastin (bevacizumab)", "type": "DRUG" }, { "name": "Tarceva (erlotinib HCl)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Genentech, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 122, "start_date": "2004-07", "completion_date": "2006-11", "has_results": false, "last_update_posted_date": "2008-01-29", "last_synced_at": "2026-10-23T12:35:30.170Z", "location_count": 48, "location_summary": "Bakersfield, California • Concord, California • Fullerton, California + 40 more", "locations": [ { "city": "Bakersfield", "state": "California" }, { "city": "Concord", "state": "California" }, { "city": "Fullerton", "state": "California" }, { "city": "Greenbrae", "state": "California" }, { "city": "Laverne", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00095225" }, { "nct_id": "NCT01160250", "title": "A Study of Vismodegib (GDC-0449) in Patients With Locally Advanced or Metastatic Basal Cell Carcinoma", "overall_status": "APPROVED_FOR_MARKETING", "study_type": "EXPANDED_ACCESS", "phases": [], "conditions": [ "Basal Cell Carcinoma" ], "interventions": [ { "name": "vismodegib (GDC-0449)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Genentech, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": null, "start_date": "2010-07", "completion_date": "2012-04", "has_results": false, "last_update_posted_date": "2015-08-06", "last_synced_at": "2026-10-23T12:35:30.170Z", "location_count": 11, "location_summary": "Scottsdale, Arizona • Los Angeles, California • Stanford, California + 7 more", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Scottsdale", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" }, { "city": "Stanford", "state": "California" }, { "city": "Ormond Beach", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT01160250" }, { "nct_id": "NCT03332797", "title": "A Study of GDC-9545 Alone or in Combination With Palbociclib and/or Luteinizing Hormone-Releasing Hormone (LHRH) Agonist in Locally Advanced or Metastatic Estrogen Receptor-Positive Breast Cancer", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Breast Cancer" ], "interventions": [ { "name": "GDC-9545", "type": "DRUG" }, { "name": "Palbociclib", "type": "DRUG" }, { "name": "LHRH Agonist", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Genentech, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 181, "start_date": "2017-11-24", "completion_date": "2027-07-31", "has_results": false, "last_update_posted_date": "2026-08-13", "last_synced_at": "2026-10-23T12:35:30.170Z", "location_count": 6, "location_summary": "Aurora, Colorado • Boston, Massachusetts • New York, New York + 1 more", "locations": [ { "city": "Aurora", "state": "Colorado" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT03332797" }, { "nct_id": "NCT00381810", "title": "A Study to Evaluate the Safety of Rituximab Retreatment in Subjects With Systemic Lupus Erythematosus", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Lupus Erythematosus, Systemic" ], "interventions": [ { "name": "Rituximab", "type": "DRUG" }, { "name": "Methylprednisolone", "type": "DRUG" }, { "name": "Acetaminophen", "type": "DRUG" }, { "name": "Diphenhydramine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Genentech, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "16 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "16 Years to 75 Years" }, "enrollment_count": 31, "start_date": "2006-06-22", "completion_date": "2012-02-29", "has_results": true, "last_update_posted_date": "2017-08-01", "last_synced_at": "2026-10-23T12:35:30.170Z", "location_count": 11, "location_summary": "Paradise Valley, Arizona • San Leandro, California • Boise, Idaho + 8 more", "locations": [ { "city": "Paradise Valley", "state": "Arizona" }, { "city": "San Leandro", "state": "California" }, { "city": "Boise", "state": "Idaho" }, { "city": "Coeur d'Alene", "state": "Idaho" }, { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT00381810" }, { "nct_id": "NCT06213311", "title": "A Study of Axicabtagene Ciloleucel and Glofitamab as Second-Line Therapy for Relapsed or Refractory Patients With Large B Cell Lymphoma", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "B Cell Lymphoma" ], "interventions": [ { "name": "Glofitamab", "type": "DRUG" }, { "name": "Obinutuzumab", "type": "DRUG" }, { "name": "Axi-cel", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 40, "start_date": "2024-05-07", "completion_date": "2027-07-31", "has_results": false, "last_update_posted_date": "2026-09-24", "last_synced_at": "2026-10-23T12:35:30.170Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT06213311" }, { "nct_id": "NCT00561834", "title": "Ranibizumab Therapy for Non-arteritic Ischemic Optic Neuropathy", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Nonarteritic Anterior Ischemic Optic Neuropathy" ], "interventions": [ { "name": "ranibizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Colorado, Denver", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "21 Years", "maximum_age": null, "sex": "ALL", "summary": "21 Years and older" }, "enrollment_count": 2, "start_date": "2007-11", "completion_date": "2009-04", "has_results": true, "last_update_posted_date": "2016-09-30", "last_synced_at": "2026-10-23T12:35:30.170Z", "location_count": 1, "location_summary": "Aurora, Colorado", "locations": [ { "city": "Aurora", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT00561834" } ] }